KAKEN PHARMACEUTICAL
Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
- Conditions
- Healty Volunteers
- Interventions
- First Posted Date
- 2025-02-12
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 36
- Registration Number
- NCT06821698
- Locations
- 🇺🇸
Parexel International Early Phase Clinical Unit, Glendale, California, United States
A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults
- Conditions
- Healthy Volunteers - Male and Female
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 40
- Registration Number
- NCT06649942
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT06619054
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
- Conditions
- Healthy Adults
- Interventions
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 38
- Registration Number
- NCT06227832
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit - Los Angeles, Glendale, California, United States
A Study to Assess the Safety of Using Fibroblast Growth Factor-2 With Periodontal Surgery in Japan (Phase 3)
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Kaken Pharmaceutical
- Target Recruit Count
- 25
- Registration Number
- NCT01015404
- Locations
- 🇯🇵
Kaken Investigational Site 5, Chiyoda-ku, Japan
🇯🇵Kaken Investigational Site 2, Matsudo, Japan
🇯🇵Kaken Investigational Site 3, Ota-ku, Japan
- Prev
- 1
- 2
- Next
News
Astria Therapeutics Secures $16 Million Japan Partnership for Hereditary Angioedema Treatment Navenibart
Astria Therapeutics has granted exclusive development and commercialization rights for navenibart in Japan to Kaken Pharmaceutical in a deal worth up to $32 million.